Validated using a knockout cell line
Recombinant
RabMAb

Anti-Bcl-2 antibody [E17] - BSA and Azide free (ab185002)

Overview

  • Product name
    Anti-Bcl-2 antibody [E17] - BSA and Azide free
    See all Bcl-2 primary antibodies
  • Description
    Rabbit monoclonal [E17] to Bcl-2 - BSA and Azide free
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WB, ICC/IF, IP, IHC-Pmore details
    Unsuitable for: Flow Cyt
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide within Human Bcl-2 aa 50-150. The exact sequence is proprietary.

  • Positive control
    • Jurkat cell lysate and human breast carcinoma.
  • General notes

    Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    This product is a recombinant rabbit monoclonal antibody.

Applications

Our Abpromise guarantee covers the use of ab185002 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use at an assay dependent concentration. Predicted molecular weight: 26 kDa.

Please check the parent abID, ab32124, for a recommended dilution.

ICC/IF Use at an assay dependent concentration.
IP Use at an assay dependent concentration.
IHC-P Use at an assay dependent concentration. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

See IHC antigen retrieval protocols.

  • Application notes
    Is unsuitable for Flow Cyt.
  • Target

    • Function
      Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release (PubMed:17418785).
    • Tissue specificity
      Expressed in a variety of tissues.
    • Involvement in disease
      A chromosomal aberration involving BCL2 has been found in chronic lymphatic leukemia. Translocation t(14;18)(q32;q21) with immunoglobulin gene regions. BCL2 mutations found in non-Hodgkin lymphomas carrying the chromosomal translocation could be attributed to the Ig somatic hypermutation mechanism resulting in nucleotide transitions.
    • Sequence similarities
      Belongs to the Bcl-2 family.
    • Domain
      BH1 and BH2 domains are required for the interaction with BAX and for anti-apoptotic activity.
      The BH4 motif is required for anti-apoptotic activity and for interaction with RAF1 and EGLN3.
      The loop between motifs BH4 and BH3 is required for the interaction with NLRP1.
    • Post-translational
      modifications
      Phosphorylation/dephosphorylation on Ser-70 regulates anti-apoptotic activity. Growth factor-stimulated phosphorylation on Ser-70 by PKC is required for the anti-apoptosis activity and occurs during the G2/M phase of the cell cycle. In the absence of growth factors, BCL2 appears to be phosphorylated by other protein kinases such as ERKs and stress-activated kinases. Phosphorylated by MAPK8/JNK1 at Thr-69, Ser-70 and Ser-87, wich stimulates starvation-induced autophagy. Dephosphorylated by protein phosphatase 2A (PP2A).
      Proteolytically cleaved by caspases during apoptosis. The cleaved protein, lacking the BH4 motif, has pro-apoptotic activity, causes the release of cytochrome c into the cytosol promoting further caspase activity.
      Monoubiquitinated by PARK2, leading to increase its stability. Ubiquitinated by SCF(FBXO10), leading to its degradation by the proteasome.
    • Cellular localization
      Mitochondrion outer membrane. Nucleus membrane. Endoplasmic reticulum membrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • Apoptosis regulator Bcl 2 antibody
      • Apoptosis regulator Bcl-2 antibody
      • Apoptosis regulator Bcl2 antibody
      • AW986256 antibody
      • B cell CLL/lymphoma 2 antibody
      • B cell leukemia/lymphoma 2 antibody
      • Bcl-2 antibody
      • Bcl2 antibody
      • BCL2_HUMAN antibody
      • C430015F12Rik antibody
      • D630044D05Rik antibody
      • D830018M01Rik antibody
      • Leukemia/lymphoma, B-cell, 2 antibody
      • Oncogene B-cell leukemia 2 antibody
      • PPP1R50 antibody
      • Protein phosphatase 1, regulatory subunit 50 antibody
      see all

    Images

    • Anti-Bcl-2 antibody [E17] - BSA and Azide free (ab185002) + MCF-7 (human breast carcinoma) whole cell lysate at 10 µg

      Secondary
      Goat Anti-Rabbit IgG H&L (HRP) (ab97051)

      Predicted band size: 26 kDa


      Exposure time: 3 minutes


      Blocking buffer and concentration: 5% NFDM/TBST

      Diluting buffer and concentration: 5% NFDM/TBST

    References

    ab185002 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab185002.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up